苄氧羰基-O-甲基-L-丝氨酰 | 134807-65-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苄氧羰基-O-甲基-L-丝氨酰
• 中文别名: 苄氧羰基-O-甲基-L-丝氨酸
• 英文名称: Z-Ser(Me)
• 英文别名: (S)-2-(((benzyloxy)carbonyl)amino)-3-methoxypropanoic acid；Cbz-Ser(OMe)-OH；N-Cbz-O-methylserine；N-benzyloxycarbonyl-D-O-methylserine；N-benzyloxycarbonyl-O-methyl-L-serine；Cbz-O-methyl-L-ser；(2S)-3-methoxy-2-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 134807-65-1
• 化学式: C₁₂H₁₅NO₅
• 分子量: 253.255
• InChiKey: LQHGCFKPNOTYIQ-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  苄氧羰基-O-甲基-L-丝氨酰 在 N-甲基吗啉 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 为溶剂， 生成 benzyl [(2R)-1-hydroxy-3-methoxypropan-2-yl]carbamate
  参考文献：
  名称：

  Madhu, Chilakapati; Panguluri, Nageswara Rao; Sureshbabu, Vommina V., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2014, vol. 53, # 7, p. 858 - 864

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl N-[(benzyloxy)carbonyl]-O-methyl-L-serinate 在 lithium hydroxide monohydrate 、 水 作用下， 以 甲醇 为溶剂， 以98%的产率得到苄氧羰基-O-甲基-L-丝氨酰
  参考文献：
  名称：

  通过二肽衍生物的脱羧环化合成多环氨基杂环

  摘要：

  报道了二肽衍生物的氧化脱羧分子内环化。苯碘( III )二乙酸酯(PIDA)与BF 3 ·OEt 2的组合促进了这种转化。该反应提供了获得各种有价值的多环 N-杂环支架的途径，这些支架包含 5-、6-或 7-元环。

  DOI：

  10.1039/d2cc00167e

文献信息

• [EN] BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE COMME INHIBITEURS DES BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016146738A1

  公开（公告）日：2016-09-22

  Compounds of formula (I) and salts thereof: wherein R1, R2, R3, R4 are defined herein. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

  式（I）的化合物及其盐：其中R1、R2、R3、R4在此处定义。已发现式（I）的化合物及其盐能够抑制BET家族的溴结构域蛋白与例如乙酰化赖氨酸残基的结合，因此可能在治疗中发挥作用，例如在治疗自身免疫和炎症性疾病（如类风湿性关节炎）和癌症方面。
• [EN] CATHEPSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA CATHEPSINE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005021487A1

  公开（公告）日：2005-03-10

  This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

  这项发明涉及一类新型化合物，由下式（I）表示，其中R1、R2、R3和R4的含义已在其中指示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物对于治疗需要抑制骨吸收的疾病非常有用，如骨质疏松症、骨关节炎和类风湿性关节炎。
• Synthesis and Anti-Helicobacter pylori Activity of Pyloricidin Derivatives. I. Structure-activity Relationships on the Terminal Peptidic Moiety.
  作者：ATSUSHI HASUOKA、YUJI NISHIKIMI、YUTAKA NAKAYAMA、KEIJI KAMIYAMA、MASAFUMI NAKAO、KEN-ICHIRO MIYAGAWA、OSAMU NISHIMURA、MASAHIKO FUJINO

  DOI：10.7164/antibiotics.55.322

  日期：——

  The novel natural antibiotics pyloricidin A, B and C possess potent and highly selective antibacterial activity against Helicobacter pylori. In order to investigate the structure activity relationships for the terminal peptidic moiety, a series of pyloricidin B and pyloricidin C derivatives, bearing various amino acids in the moiety, were prepared and evaluated for their anti-H. pylori activity. The derivatives bearing α-D-, β- and γ-amino acids or peptidemimetics showed drastically decreased activity. On the other hand, the derivatives with α-L-amino acids were found to maintain the activity. Among the derivatives prepared in this work, the allylglycine derivative 2s showed the most potent anti-H. pylori activity, with an MIC value of less than 0.006μg/ml against H. pylori NCTC11637, which is 60-fold greater than the activity of the lead compound pyloricidin C.

  新型天然抗生素喷菌素A、B和C对幽门螺杆菌具有强效且高度选择性的抗菌活性。为了研究末端肽部分的结构-活性关系，制备了一系列含不同氨基酸的喷菌素B和喷菌素C衍生物，并评估了它们的抗幽门螺杆菌活性。含有α-D-、β-和γ-氨基酸或肽模拟物的衍生物显示出显著降低的活性。另一方面，含有α-L-氨基酸的衍生物被发现能保持活性。在本工作中制备的衍生物中，烯丙基甘氨酸衍生物2s表现出最强的抗幽门螺杆菌活性，对幽门螺杆菌NCTC11637的最低抑制浓度（MIC）值小于0.006μg/ml，比原始化合物喷菌素C的活性高出60倍。
• Substituted oxoazaheterocyclyl compounds
  申请人：AVENTIS PHARMACEUTICALS INC.

  公开号：US20040102450A1

  公开（公告）日：2004-05-27

  This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

  这项发明涉及抑制因子Xa的氧杂杂环化合物，抑制同时抑制因子Xa和因子IIa的氧杂杂环化合物，包含这些化合物的药物组合物，用于制备这些化合物的中间体，直接抑制因子Xa的方法，以及同时直接抑制因子Xa和因子IIa的方法。
• Cyclic amine compounds
  申请人：Hasuoka Atsushi

  公开号：US20090042967A1

  公开（公告）日：2009-02-12

  The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhancers, muscle increasing agents, cachexia suppressants, body weight decrease suppressants, agents for the prophylaxis or treatment of prostate hypertrophy, amyotrophy or muscle loss caused by a disease or an agent for reducing the prostate weight. The present invention also relates to methods for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis in a mammal, which comprises administering an effective amount of the pharmaceutical agents of the present invention or a prodrug thereof; use of the pharmaceutical agents of the present invention or a prodrug thereof for the production of an agent for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; and the like.

  本发明涉及用于预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的药物剂，其中包括虚弱抑制剂、肌肉力量增强剂、肌肉增长剂、消瘦抑制剂、体重减少抑制剂、用于预防或治疗前列腺肥大、肌萎缩或疾病引起的肌肉流失或降低前列腺重量的药物剂。本发明还涉及一种在哺乳动物中预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的方法，包括向其投予本发明的药物剂或其前药的有效量；使用本发明的药物剂或其前药生产用于预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的药物剂；等等。